Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...
Drug
MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...
Zhejiang Huahai Pharmaceutical’s HB0052 Receives US FDA IND Approval for Solid Tumors
IntroductionZhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...
BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE
The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab)...
Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has...
Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase...
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...
Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its...
Gaush Meditech Ltd Receives NMPA Approval for Rigid Corneal Contact Lens
Gaush Meditech Ltd (HKG: 2407), a company based in Suzhou, has announced that it has...
Wuhan Hiteck Biological Pharma Receives NMPA Approval for Aponermin in Multiple Myeloma Treatment
Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that...
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...